



Proteomics International
LABORATORIES LTD

ASX/Media Release

14 March 2018

ASX code: PIQ

Proteomics secures underwriting – PIQ Options exercise to raise \$3.4 million

- **Proteomics secures underwriting for \$2 million of PIQO options**
- **Early exercise from existing Option holders brings in over \$400,000**
- **Directors undertake to exercise \$1 million of PIQO options**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) has secured commitments to raise \$3.4 million from exercise of its Options (ASX: PIQO) expiring 31 March 2018. The total number of PIQO options on issue at 31 December 2017 was 17,231,856, with the potential to raise \$3.4 million if fully exercised.

Proteomics International has entered into an agreement with Alto Capital to underwrite the last \$2 million of any shares arising from Options not taken up by existing Option holders. Early exercise of Options from existing holders has already raised \$430,146. The Directors have also undertaken to exercise their options to raise another \$1 million.

The funds will be available once all Options are fully exercised (expiry date 31 March 2018) and place Proteomics International in a strong financial position to continue to leverage the Promarker™ technology across the integrated areas of analytical services, diagnostics and therapeutics.

The underwriting agreement contains terms normally found in agreements of this nature, including the usual indemnification and termination provisions and provides for an underwriting fee of 6% (excluding GST) calculated on the underwritten amount. In accordance with Listing Rule 3.11.3, the Company confirms the underwriter is ACNS Capital Markets Pty Ltd ATF The ACNS Unit Trust trading as Alto Capital (AFSL 279099). The Company intends to issue shortfall shares upon conversion of the unexercised PIQO options pursuant to the underwriting agreement and in accordance with ASX Listing Rule 7.2 (exception 12) and accordingly shareholder approval will not be sought.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

PILL (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com